Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained

Blood

Volumn 124, Issue 7, 2014, Pages 1099-1109

  Vandenberg, Cassandra J ^a,b   Waring, Paul ^c   Strasser, Andreas ^a,b   Cory, Suzanne ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BH3 PROTEIN; BIM PROTEIN; CYCLIN D; MYC PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; CYCLIN D1; MCL1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MYELOID LEUKEMIA FACTOR 1; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENOTYPE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE C MYC; PLASMA CELL; PLASMACYTOMA; PLASMACYTOMAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPLE MYELOMA; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PLASMACYTOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905976792     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570770     Document Type: Article

References (79)

1. Potter M. Neoplastic development in plasma cells. Immunol Rev. 2003;194:177-195. (Pubitemid 36886436)
2. Cory S, Bernard O, Gerondakis S, et al. Interchromosomal translocation of the c-myc oncogene in B lymphoid tumours: structural and functional consequences. Prog Immunol. 1983;(V)149-158.
3. Klein G. Multiple phenotypic consequences of the Ig/Myc translocation in B-cell-derived tumors. Genes Chromosomes Cancer. 1989;1(1):3-8. (Pubitemid 20093333)
4. Bernard O, Cory S, Gerondakis S, Webb E, Adams JM. Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J. 1983;2(12):2375-2383.
5. Rosenbaum H, Harris AW, Bath ML, et al. An Eμ-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J. 1990;9(3):897-905.
6. Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res. 1988;35:39-81.
7. Goff SP. The Abelson murine leukemia virus oncogene. Proc Soc Exp Biol Med. 1985;179(4):403-412. (Pubitemid 15023153)
8. Cook WD. Thymocyte subsets transformed by Abelson murine leukemia virus. Mol Cell Biol. 1985;5(2):390-397. (Pubitemid 15166304)
9. Harris AW, Bath ML, Rosenbaum H, McNeall J, Adams JM, Cory S. Lymphoid tumorigenesis by v-abl and BCR-v-abl in transgenic mice. Curr Top Microbiol Immunol. 1990;166:165-173.
10. Symons RC, Daly MJ, Fridlyand J, et al. Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in Eμ-v-abl transgenic mice. Proc Natl Acad Sci USA. 2002;99(17):11299-11304. (Pubitemid 34920920)
11. Mock BA, Krall MM, Dosik JK. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA. 1993;90(20):9499-9503. (Pubitemid 23315812)
12. Potter M, Sklar MD, Rowe WP. Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice. Science. 1973;182(4112):592-594.
13. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180. (Pubitemid 351163163)
14. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.
15. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738. (Pubitemid 129515880)
16. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 1991;67(5):889-899. (Pubitemid 121001503)
17. Strasser A, Harris AW, Corcoran LM, Cory S. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature. 1994;368(6470):457-460. (Pubitemid 24115352)
18. Campbell KJ, Bath ML, Turner ML, et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood. 2010;116(17):3197-3207.
19. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68(5):869-877.
20. Kallies A, Hasbold J, Tarlinton DM, et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J Exp Med. 2004;200(8):967-977. (Pubitemid 39431122)
21. MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev. 2003;194:8-18. (Pubitemid 36886424)
22. Jacob J, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl) acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med. 1992;176(3):679-687.
23. Peperzak V, Vikström I, Walker J, et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol. 2013;14(3):290-297.
24. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA. 1991;88(19):8661-8665. (Pubitemid 21915417)
25. Linden M, Kirchhof N, Carlson C, Van Ness B. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 2004;103(7):2779-2786. (Pubitemid 38393037)
26. Cheung WC, Kim JS, Linden M, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004;113(12):1763-1773. (Pubitemid 39071668)
27. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 1986;47:189-234.
28. Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014.
29. Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology (Am Soc Hematol Educ Program). 2011;2011:344-353.
30. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69(1):119-128.
31. Strasser A, Elefanty AG, Harris AW, Cory S. Progenitor tumours from Eμ-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 1996;15(15):3823- 3834. (Pubitemid 26289792)
32. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998;12(19):2984-2991. (Pubitemid 28469300)
33. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669. (Pubitemid 29508553)
34. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1991;88(12):5413-5417. (Pubitemid 21914755)
35. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma. 1996;21(5-6):391-397. (Pubitemid 26141222)
36. Møller MB, Ino Y, Gerdes AM, Skjødt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia. 1999;13(3):453-459. (Pubitemid 29108084)
37. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101(16):6164-6169. (Pubitemid 38520545)
38. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848. (Pubitemid 38174664)
39. Strasser A, Bouillet P. The control of apoptosis in lymphocyte selection. Immunol Rev. 2003;193:82-92. (Pubitemid 36688042)
40. Tagawa H, Karnan S, Suzuki R, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 2005;24(8):1348-1358. (Pubitemid 40343115)
41. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49-63.
42. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403. (Pubitemid 40193310)
43. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17(4):525-535. (Pubitemid 40269117)
44. Boylan KL, Gosse MA, Staggs SE, et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res. 2007;67(9):4069-4078. (Pubitemid 46815051)
45. Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004;118(4):431-438. (Pubitemid 39485663)
46. Cong F, Zou X, Hinrichs K, Calame K, Goff SP. Inhibition of v-Abl transformation by p53 and p19ARF. Oncogene. 1999;18(54):7731-7739. (Pubitemid 30061352)
47. Goldberg Z, Vogt Sionov R, Berger M, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002;21(14):3715-3727. (Pubitemid 34787045)
48. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35.
49. Lüscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene. 2012;494(2):145-160.
50. Shore SK, Tantravahi RV, Reddy EP. Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene. 2002;21(56):8568-8576. (Pubitemid 36084189)
51. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183. (Pubitemid 40314949)
52. Park ES, Shaughnessy JD Jr, Gupta S, et al. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007;8:302.
53. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304(5927):596-602. (Pubitemid 13035496)
54. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of Eμ-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol. 1989;9(1):67-73. (Pubitemid 19024779)
55. Alexander WS, Bernard O, Cory S, Adams JM. Lymphomagenesis in Eμ-myc transgenic mice can involve ras mutations. Oncogene. 1989;4(5):575-581. (Pubitemid 19139709)
56. Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death Differ. 2012;19(7):1220-1227.
57. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 2011;10(1):57-67.
58. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22(2):167-179.
59. Largaespada DA, Kaehler DA, Mishak H, et al. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene. 1992;7(4):811-819.
60. Weissinger EM, Mischak H, Goodnight J, Davidson WF, Mushinski JF. Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas. Mol Cell Biol. 1993;13(4):2578-2585. (Pubitemid 23097736)
61. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18(19):5321-5333. (Pubitemid 29465582)
62. Yu Q, Ciemerych MA, Sicinski P. Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins. Oncogene. 2005;24(47):7114-7119. (Pubitemid 41573640)
63. Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001;15(16):2042-2047. (Pubitemid 32762047)
64. Philipp A, Schneider A, Väsrik I, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol. 1994;14(6):4032-4043. (Pubitemid 24160809)
65. Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA. 1995;92(21):9540-9544.
66. Nakamura Y, Grumont RJ, Gerondakis S. NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression. Mol Cell Biol. 2002;22(15):5563-5574. (Pubitemid 34755765)
67. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558-572.
68. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13(9):2124-2130. (Pubitemid 24139725)
69. Lovec H, Grzeschiczek A, Kowalski M-B, Möröy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13(15):3487-3495. (Pubitemid 24246185)
70. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
71. Lohr JG, Stojanov P, Carter SL, et al Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
72. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456-3463.
73. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21(44):6848-6857. (Pubitemid 35221928)
74. Wuillème-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248-1252. (Pubitemid 40946011)
75. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004;3(10):1259-1262. (Pubitemid 40268607)
76. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol. 2004;34(11):3156-3164. (Pubitemid 39549394)
77. Lin FR, Kuo HK, Ying HY, Yang FH, Lin KI. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. Cancer Res. 2007;67(24):11914-11923.
78. Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 2008;112(6):2450-2462.
79. Okamoto T, Coultas L, Metcalf D, et al. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proc Natl Acad Sci USA. 2014;111(1):261-266.